CA3058492A1 - Radiotherapy improvements - Google Patents

Radiotherapy improvements Download PDF

Info

Publication number
CA3058492A1
CA3058492A1 CA3058492A CA3058492A CA3058492A1 CA 3058492 A1 CA3058492 A1 CA 3058492A1 CA 3058492 A CA3058492 A CA 3058492A CA 3058492 A CA3058492 A CA 3058492A CA 3058492 A1 CA3058492 A1 CA 3058492A1
Authority
CA
Canada
Prior art keywords
individual
tumours
alkyl
compound
irradiated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3058492A
Other languages
English (en)
French (fr)
Inventor
Graham Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noxopharm Ltd
Original Assignee
Noxopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/AU2016/050674 external-priority patent/WO2017173474A1/en
Application filed by Noxopharm Ltd filed Critical Noxopharm Ltd
Publication of CA3058492A1 publication Critical patent/CA3058492A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3058492A 2016-04-06 2017-04-06 Radiotherapy improvements Abandoned CA3058492A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662318946P 2016-04-06 2016-04-06
US62/318,946 2016-04-06
AUPCT/AU2016/050674 2016-07-28
PCT/AU2016/050674 WO2017173474A1 (en) 2016-04-06 2016-07-28 Improvements in cancer treatment
US201762461559P 2017-02-21 2017-02-21
US62/461,559 2017-02-21
PCT/AU2017/050299 WO2017173496A1 (en) 2016-04-06 2017-04-06 Radiotherapy improvements

Publications (1)

Publication Number Publication Date
CA3058492A1 true CA3058492A1 (en) 2017-10-12

Family

ID=60000154

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3058492A Abandoned CA3058492A1 (en) 2016-04-06 2017-04-06 Radiotherapy improvements

Country Status (6)

Country Link
US (2) US11229703B2 (OSRAM)
EP (1) EP3439642A4 (OSRAM)
JP (1) JP2019513826A (OSRAM)
AU (1) AU2017247006B2 (OSRAM)
CA (1) CA3058492A1 (OSRAM)
WO (1) WO2017173496A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3439642A4 (en) * 2016-04-06 2019-11-13 Noxopharm Limited IMPROVEMENTS IN RADIOTHERAPY
CA3169406A1 (en) 2020-01-28 2021-08-05 Reflexion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
AUPQ008299A0 (en) 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites
US20090233999A1 (en) * 1999-09-06 2009-09-17 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPR363301A0 (en) * 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
CN1646119A (zh) 2002-04-09 2005-07-27 诺沃根研究有限公司 涉及异黄－3－烯和异黄烷结构的治疗方法和组合物
EP1545206B1 (en) 2002-07-24 2020-03-04 Children's Hospital Medical Center Compositions and products containing enantiomeric equol, and methods for their making
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
AU2002952453A0 (en) * 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
MXPA06003066A (es) * 2003-09-18 2006-06-20 Combinatorx Inc Combinaciones de farmacos para el tratamiento de neoplasmas.
JP2007525485A (ja) * 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
US20050154452A1 (en) 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US7434690B2 (en) 2004-04-30 2008-10-14 Cutispharma, Inc. Container and method for the preparation, storage and dispensing of compounded suppositories
US8080675B2 (en) * 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
AU2005287865B2 (en) * 2004-09-21 2012-02-16 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
WO2006032086A1 (en) 2004-09-21 2006-03-30 Novogen Research Pty Ltd Chroman derivatives, medicaments and use in therapy
DE102005009515A1 (de) 2005-02-25 2006-09-07 Exner, Heinrich, Dr. Verfahren zur Herstellung einer Zubereitung einer DMSO-haltigen festen Silikonölemulsion zur Bindung von reaktiven Sauerstoffverbindungen im Körper von Menschen und Tieren
JP2008537545A (ja) 2005-03-24 2008-09-18 ノボジェン リサーチ ピーティーワイ リミテッド イソフラボノイド二量体
WO2007035515A2 (en) 2005-09-15 2007-03-29 Umd, Inc. A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration
US20070196381A1 (en) 2006-02-17 2007-08-23 Natures Benefit, Inc. Herbal compositions, methods of stimulating immunomodulation and enhancement of immunomodulating agents using the herbal compositions
CA2668008A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
WO2009003229A1 (en) 2007-06-29 2009-01-08 Novogen Research Pty Ltd 2-substituted isoflavonoid compounds, medicaments and uses
WO2010022467A1 (en) 2008-08-29 2010-03-04 Novogen Research Pty Ltd Immunomodulating activities
EP2365955B1 (en) 2008-11-14 2014-12-31 Heartlink Limited Aryl di-substituted propenone compounds
KR20110004525A (ko) 2009-07-08 2011-01-14 동의대학교 산학협력단 제니스테인과 ｔｒａｉｌ을 포함하는 간암 치료용 조성물
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
AU2012323924A1 (en) * 2011-10-14 2014-05-29 The Ohio State University Methods and materials related to ovarian cancer
RS59013B1 (sr) * 2013-03-13 2019-08-30 Oncoceutics Inc 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za upotrebu u lečenju kancera
US20150126597A1 (en) * 2013-11-07 2015-05-07 Humanetics Corporation Genistein cancer treatment regimen maximizing cancer radiation therapy benefits
BR112016018099B8 (pt) * 2014-02-07 2023-01-17 Novogen ltd Compostos funcionalizados de benzopiranos e uso dos mesmos
SI3334431T1 (sl) 2015-08-11 2020-01-31 Novartis Ag 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka
WO2017079746A2 (en) * 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
EP3939583A1 (en) * 2016-04-06 2022-01-19 Noxopharm Limited Improvements in cancer treatment with isoflavonoids
EP3439642A4 (en) * 2016-04-06 2019-11-13 Noxopharm Limited IMPROVEMENTS IN RADIOTHERAPY
EP3439644B1 (en) 2016-04-06 2022-01-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
AU2017254774B2 (en) * 2016-04-22 2021-10-21 Noxopharm Limited Chemotherapy improvements
EP3806846A1 (en) 2018-06-15 2021-04-21 Board of Regents, The University of Texas System Methods of treating and preventing breast cancer with s-equol
JP2021535187A (ja) 2018-06-15 2021-12-16 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System Ｓ−エクオールを用いた黒色腫の処置及び予防方法
WO2020051644A1 (en) 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation

Also Published As

Publication number Publication date
AU2017247006B2 (en) 2022-05-12
US20220105182A1 (en) 2022-04-07
WO2017173496A1 (en) 2017-10-12
AU2017247006A1 (en) 2018-11-01
EP3439642A1 (en) 2019-02-13
US20190262451A1 (en) 2019-08-29
JP2019513826A (ja) 2019-05-30
US11229703B2 (en) 2022-01-25
EP3439642A4 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
Rini Future approaches in immunotherapy
JP7772748B2 (ja) 治療用ナノ生物学的組成物による訓練免疫の促進
CN109069512A (zh) 取代的氨基嘌呤化合物、其组合物以及相关治疗方法
JP7490361B2 (ja) ｉｎ ｓｉｔｕ免疫調節癌ワクチン接種のための放射性ハロゲン化剤
KR20170017933A (ko) 암의 치료를 위한 조합 요법
JP2016540042A (ja) がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
JP7627259B2 (ja) 抗ｃｄ２５抗体－フタロシアニン色素コンジュゲートおよび抗ｐｄ１抗体を使用したがんの処置のための近赤外（ｎｉｒ）光免疫療法（ｐｉｔ）
Kerbel Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs
US20220105182A1 (en) Radiotherapy improvements
Zhang et al. Immune therapy in pancreatic cancer: now and the future?
Buchsel et al. Dendritic cells: emerging roles in tumor immunotherapy
Rüttinger et al. Current immunotherapeutic strategies in lung cancer
Massumoto et al. Complete remission of mantle-cell non-Hodgkin lymphoma with a dendritic cell vaccine
Osei et al. A review of radiation induced abscopal effect: combining radiotherapy and immunotherapy to treat the untreated distant metastatic tumours
Klautke et al. PD (L) 1-Inhibitors and Radiation: A Good Combination for Local and Systemic Effects?
MM et al. Exploration of Personalized Treatment for Advanced Hepatocellular Carcinoma: Combination Therapy of Selinexor, Palbociclib, and Pembrolizumab with Umbilical Cord Blood NK Cells
Chaturvedi et al. Immunotherapy for breast cancer
전석주 Immunomodulatory Effects of Low-Dose Cyclophosphamide with Radiotherapy
Chan Understanding cancer therapies
Vodeneev et al. Targeted radionuclide therapy: current status and prospects
Koontz et al. Principles of radiation oncology
Hurria Breast cancer: medical management of early stage breast cancer
Ezziddin et al. Correspondence (letter to the editor): Radioembolization as a Treatment Option
Tsamaloukas Correspondence (letter to the editor): Isocitrate Dehydrogenase Genes
Arndt Vogel et al. The Diagnosis and Treatment of Cholangiocarcinoma

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230704